Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | FLT1 | P17948 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3717313 | 0.87 | GPR142 (0.37) | GPR142PIK3CACREBBPNAMPTAURKA | |
| SCHEMBL861444 | 0.78 | PIK3CA (0.40) | GPR142PIK3CACREBBP | |
| SCHEMBL858099 | 0.78 | RPS6KB1 (0.36) | GPR142CREBBPAURKAFLT1GCK | |
| SCHEMBL862212 | 0.76 | RPS6KB1 (0.35) | GPR142CREBBPAURKAFLT1GCK | |
| SCHEMBL856826 | 0.74 | KIT (0.35) | GPR142PIK3CA | |
| SCHEMBL856691 | 0.74 | PIK3CA (0.34) | GPR142PIK3CACREBBPAURKAFLT1 | |
| SCHEMBL856395 | 0.73 | GPR142 (0.34) | GPR142 | |
| SCHEMBL7806917 | 0.72 | PIK3CA (0.46) | GPR142PIK3CACREBBP | |
| SCHEMBL15522613 | 0.71 | PIK3CA (0.40) | PIK3CACREBBP | |
| SCHEMBL3756056 | 0.70 | PIK3CA (0.43) | GPR142PIK3CACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080810-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | GPR142 2004/4885PIK3CA 3/4885CREBBP 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.